Coronary CTA to Investigate Predictive Value of Left Atrial Appendage for Cardiogenic Stroke in Patients with Nonvalvular Atrial Fibrillation

Runrong Wang, Chunhong Hu, Zheng Li, Shuai Zhang, Wei Li, and Hongling Hou

1Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province 215006, China
2Department of Radiology, Medical Imaging Center, The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu Province 225001, China
3Department of Neurology, The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu Province 225001, China
4Department of Cardiology, The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu Province 225001, China

Correspondence should be addressed to Chunhong Hu; hch5676sz@163.com

Received 23 May 2020; Revised 25 September 2020; Accepted 29 September 2020; Published 15 October 2020

1. Introduction

As defined in the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation, nonvalvular atrial fibrillation (NVAF) refers to an atrial fibrillation that occurs in patients without rheumatic mitral valve disease, mechanical or biological valve replacement, and mitral anuloplasty [1]. With the aging of the population structure, the incidence of NVAF has increased year by year. According to a recent epidemiological survey, the incidence of NVAF is about 10% in people over 75 years old [2, 3]. The annual incidence of cardiogenic stroke in patients with NVAF is about 5%, which is 2 to 7 times that of sinus rhythm [4]. Compared with other types of ischemic stroke, cardiogenic stroke has higher hemorrhagic transformation, disability, and mortality and the prognosis is poor [5, 6]. Cardiogenic...
stroke also has a high rate of early recurrence, with a recurrence rate of approximately 12% within 2 weeks of the onset of initial symptoms [7, 8]. How to effectively control and prevent cardiogenic stroke is a challenge for the academic community, and exploring the risk factors associated with cardiogenic stroke is the essential point. The left atrial appendage (LAA) as the main part of the formation of responsible emboli in cardiogenic stroke in patients with atrial fibrillation, and its influence on the progress of disease has become the focus of current research. Currently, clinicians generally rely on the CHA2DS2-VASc scoring system to assess the risk of embolism in patients with atrial fibrillation and to guide anticoagulant therapy. However, a single assessment indicator often fails to meet practical needs. The aim of this study was to investigate the effect of quantitative indicators of anatomy and function of LAA on the risk of cardiogenic stroke in patients with NVAF by coronary CTA and to provide valuable imageology reference for the design of clinical anticoagulation program.

2. Materials and Methods

2.1. Research Object. In the beginning, a total of 385 patients with NVAF who underwent coronary CTA examination to assess the condition of coronary arteries between January 2014 and June 2017 were selected. Atrial fibrillation was diagnosed according to the conventional 12-lead electrocardiogram (ECG) or 24-hour Holter. Collect demographic data, clinical history data, and laboratory and imageology findings of these patients, and exclude the following: (1) history of rheumatic mitral valve disease, congenital heart disease, and cardiomyopathy; (2) history of various types of cardiac surgery; (3) history of pulmonary embolism or deep vein thrombosis; (4) coronary CTA scan range does not include the whole LAA, or LAA is poorly displayed; (5) and presence of LAA thrombosis. Consequently, 326 patients were enrolled and were followed up for 2 years. The patients were classified based on the outbreak of acute ischemic stroke and transient ischemic attack (TIA) within 2 years after coronary CTA examination and were further classified based on the TOAST classification criteria. During the follow-up period, 147 patients were excluded including those who met the TOAST criteria for noncardiogenic stroke, patients with TIA attacks, and some lost to follow-up. Of the remaining 179 cases, 87 patients with cardiogenic stroke were selected as the case group and 92 patients with neither acute ischemic stroke nor TIA during the follow-up period were selected as the control group. The diagnosis of stroke and TIA is based on the results of head MR examination and clinical manifestations and is consensually diagnosed by two neurologists with more than 10 years of practicing experience. Because the age composition of population in this study was mainly elderly (63.9 ± 8.4 yrs), the overall compliance with long-term anticoagulation therapy was poor. In addition, some patients discontinued the drug due to bleeding risk or other factors during the follow-up period. Therefore, the proportion of patients continuously using anticoagulants in both groups in this study was low, and there was no statistical difference between the groups (9.2% vs 12.0%, \( \chi^2 = 0.359, P = 0.549 \)). Warfarin was used for anticoagulation in all patients except for one patient who used Dabigatran etexilate in each of the two groups. The study was approved by the ethics committee, and patients who participated in the study signed an informed consent.

2.2. Examination Method. The patients’ heart rates were controlled at 50-75 beats/min, and those with a faster heart rate were given oral 25 mg metoprolol. Before the examination, the patients were given breath-holding training. The patients were placed in a supine position in the examination and were scanned at the end of the expiration when holding their breath. The breath holding time was about 4 to 6 seconds. The cardiac CTA scan was performed using a 128-slice CT scanner (SOMATOM Definition AS CT, Siemens Medical, Forchheim, Germany). Scanning parameter was as follows: tube voltage 120–140 KV, tube current 180–200 mAs, automatic matching pitch, collimator width 128 × 0.6 mm, FOV 180–210 mm, convolution kernel B35f and B46f, scanning time 4–6s. Retrospective ECG gating was used. Scan range was from 1 cm above the tracheal bifurcation to 1 cm below the diaphragm face of the heart. The contrast agent concentration monitoring layer was placed at the root of the ascending aorta, and the scan is initiated when the CT value in the ROI exceeds a preset threshold (160 HU). The contrast agent (Ultravist 370 mg/ml, dose 1.0 ml/kg) in combination with physiological saline 70 ml (20 ml before injection of a contrast agent, 50 ml after injection of a contrast agent) was injected through the median elbow vein at a rate of 5.0 ml/s using a double-tube high-pressure syringe.

3. Image Postprocessing and Measurement

Postprocessing and measurement were performed jointly by two radiologists who were blinded to clinical data (including history of stroke/TIA), using dedicated software (Syngo MMWP VE32D, Siemens Medical, Forchheim, Germany) on the workstation. Consensus was obtained for each case. In the beginning, with the assistance of a cardiologist, the two radiologists were trained on an initial sample of 20 cases to standardize the image reconstruction of LAA and parameter measurement. The maximum and minimum diameters of the left atrial appendage orifice (LAAODmax and LAAODmin), the left atrial appendage orifice area (LAAOA), the left atrial appendage depth (LAAD), the left atrial appendage volume (LAAV), the correction index of corresponding parameter, and the left atrial appendage emptying fraction (LAAEF) were obtained as follows: (1) the multiplanar reformation (MPR) was performed at the junction of LAA and left atrium (reference demarcation mark: a line connecting 1~2 cm below the left upper pulmonary vein orifice with the left coronary artery originating position), and a short-axis view of the LAA orifice was obtained that can be used to measure the LAAODmax, LAAODmin, and LAAOA (see Figures 1(a)–1(c)); (2) curved planar reformation (CPR) along the LAA long-axis and measuring the distance from the center of the LAA orifice to the LAA vertex on the CPR recombination image to obtain the LAAD (see Figures 1(d)–1(e)); (3) using the reconstructed images of
each phase, manually tracing the endocardial border of the individual short-axis segments by the volumetric measurement tool to calculate the LAAV of each phase by the layer-stacking method (see Figure 2), and determining the maximum LAAV (LAAVmax) and the minimum LAAV (LAAVmin); (4) using the body surface area (BSA) to correct each measured parameter to obtain the correction index of the corresponding parameter: value index = value/BSA; and (5) the LAAEF was calculated using the following equation: 

$LAAEF = \frac{(LAAV_{\text{max}} - LAAV_{\text{min}})}{LAAV_{\text{max}}} \times 100\%$

3.1. Statistical Analysis. Statistical analysis was performed using SPSS 17.0 and Med Calc 15.0 statistical software. Continuous data close to the normal distribution were expressed as mean ± standard deviation ($\bar{x} \pm s$), and non-normally distributed data were expressed as median (lower quartile – upper quartile). Categorical data were presented as absolute numbers (percentages). Differences in continuous variables between the two groups were assessed using Student’s t-test or Mann–Whitney U-test, as appropriate. Differences in categorical variables between the two groups were assessed using a Pearson chi-square test. The difference was considered statistically significant at $P < 0.05$. The impacts of body mass index (BMI), hyperlipidemia, the duration of atrial fibrillation, LAAOA Index, and LAAEF on cardiogenic stroke were assessed by a binary logistic regression analysis, and the continuous data had been grouped into quartiles. We adopted a forward stepwise regression method based on maximum likelihood estimation for the variable screening method. To assess the ability of LAAOA Index, LAAEF, and the combined predictor of LAAOA Index and LAAEF in predicting cardiogenic stroke, receiver operating characteristic (ROC) curves were constructed. The AUC value (area under the ROC curve) was used as a scalar measure to assess the performance of each parameter. The AUC value for different parameters were compared by a Z test; $P < 0.05$ was considered statistically significant.

4. Results

The demographic and clinical data of the two groups are listed in Table 1. The proportion of overweight or obesity (BMI ≥ 25) (71.3% vs 51.1%, $X^2 = 7.645, P = 0.006$) and the prevalence of hyperlipidemia (59.8% vs 42.4%, $X^2 = 5.404, P = 0.020$) in the case group were higher than those in the control group. The duration of atrial fibrillation was longer in the case group than that in the control group [5 (3-9) yrs vs 4 (2-7) yrs, $Z = -2.995, P = 0.003$]. There were no significant differences between two groups in terms of gender,
age, body surface area (BSA), smoking history, drinking history, hypertension, diabetes, coronary heart disease, CHA2DS2-VASc score, continuous use of anticoagulants during the follow-up period, and atrial fibrillation type (paroxysmal atrial fibrillation vs persistent or permanent atrial fibrillation, similarly hereinafter).

The parameters derived from coronary CTA are shown in Table 2. The LAAOmax (3.31 ± 0.38 cm vs 2.97 ± 0.38 cm, \( t = 5.862, P < 0.001 \)) with its correction index (1.80 ± 0.21 cm/m² vs 1.64 ± 0.24 cm/m², \( t = 4.783, P < 0.001 \)), LAAODmin (2.18 ± 0.32 cm vs 1.93 ± 0.33 cm, \( t = 5.212, P < 0.001 \)) with its correction index (1.19 ± 0.17 cm²/m² vs 1.06 ± 0.19 cm²/m², \( t = 4.647, P < 0.001 \)), LAAOA (5.90 ± 1.36 cm² vs 4.80 ± 1.14 cm², \( t = 5.820, P < 0.001 \)) with its correction index (3.20 ± 0.71 cm²/m² vs 2.65 ± 0.64 cm²/m², \( t = 5.481, P < 0.001 \)), LAAVmax (14.58 ± 3.73 ml vs 12.02 ± 3.16 ml, \( t = 4.946, P < 0.001 \)) with its correction index (7.91 ± 1.92 ml/m² vs 6.61 ± 1.68 ml/m², \( t = 4.826, P < 0.001 \)), and LAAVmin (9.27 ± 2.69 ml vs 6.66 ± 2.38 ml, \( t = 6.877, P < 0.001 \)) with its correction index (5.03 ± 1.40

### Table 1: Comparison of demographic and clinical data between the two groups.

| Characteristics                  | Total (n = 179) | Cases (n = 87) | Controls (n = 92) | Statistic value | P value |
|----------------------------------|----------------|---------------|------------------|-----------------|---------|
| Sex, n (%)                       |                |               |                  |                 |         |
| Male                             | 102 (57.0)     | 48 (55.2)     | 54 (58.7)        | 0.226*          | 0.634   |
| Female                           | 77 (43.0)      | 39 (44.8)     | 38 (41.3)        |                 |         |
| Age, yrs (mean ± SD)             | 63.9 ± 8.4     | 64.5 ± 8.1    | 63.2 ± 8.6       | 1.013*          | 0.312   |
| BSA, n (%)                       | 1.83 ± 0.14    | 1.84 ± 0.14   | 1.82 ± 0.15      | 1.033*          | 0.303   |
| BMI, n (%)                       |                |               |                  |                 |         |
| ≥25                              | 109 (60.9)     | 62 (71.3)     | 47 (51.1)        | 7.645*          | 0.006   |
| <25                              | 70 (39.1)      | 25 (28.7)     | 45 (48.9)        |                 |         |
| Tobacco use, n (%)               | 54 (30.2)      | 27 (31.0)     | 27 (29.3)        | 0.060*          | 0.806   |
| Alcohol use, n (%)               | 15 (8.4)       | 7 (8.0)       | 8 (8.7)          | 0.025*          | 0.875   |
| Hypertension, n (%)              | 107 (59.8)     | 55 (63.2)     | 52 (56.5)        | 0.834*          | 0.361   |
| Hyperlipidemia, n (%)            | 91 (50.8)      | 52 (59.8)     | 39 (42.4)        | 5.404*          | 0.020   |
| Diabetes mellitus, n (%)         | 35 (19.6)      | 19 (21.8)     | 16 (17.4)        | 0.562*          | 0.453   |
| Coronary disease, n (%)          | 79 (44.1)      | 40 (46.0)     | 39 (42.4)        | 0.233*          | 0.629   |
| AF, n (%)                        |                |               |                  |                 |         |
| Prxm AF                          | 93 (52.0)      | 44 (50.6)     | 49 (53.3)        | 0.129*          | 0.719   |
| Pst or pmnt AF                   | 86 (48.0)      | 43 (49.4)     | 43 (46.7)        |                 |         |
| AF duration (yrs [md(Q1-Q3)])    | 4 (2-8)        | 5 (3-9)       | 4 (2-7)          | -2.995**        | 0.003   |
| CHA2DS2-VASc score, n (%)        |                |               |                  |                 |         |
| ≥2                               | 131 (73.2)     | 65 (74.7)     | 66 (71.7)        | 0.201*          | 0.654   |
| <2                               | 48 (26.8)      | 22 (25.3)     | 26 (28.3)        |                 |         |
| Anticoagulant use, n (%)         | 19 (10.6)      | 8 (9.2)       | 11 (12.0)        | 0.359*          | 0.549   |

Numerical data are expressed as the mean ± standard deviation. Categorical data as numbers (percentages). Nonparametric data are expressed as the median (interquartile range). BSA: body surface area; BMI: body mass index; AF: atrial fibrillation; Prxm AF: paroxysmal atrial fibrillation; Pst or pmnt AF: persistent or permanent atrial fibrillation, respectively. *X² value, †t value, **Z value.
LAAODmax and LAAODmin: maximum and minimum left atrial appendage orifice diameter, respectively; LAAODmax/LAAODmin: ratio of LAAODmax to LAAODmin; LAAOA: left atrial appendage orifice area; LAAD: left atrial appendage depth; LAVmax and LAVmin: maximum and minimum left atrial appendage volume; one value index: ratio of the one value to body surface area (BSA); LAAEF: left atrial appendage emptying fraction.

| Variable | Odds ratio | 95% confidence interval for odds ratio | P value |
|----------|------------|---------------------------------------|---------|
| LAAOA Index (cm²/m²) | | | |
| ≤ 2.36  | 1.799 | 0.693–4.670 | 0.228 |
| 2.37–2.86 | 1.930 | 0.726–5.129 | 0.187 |
| 2.87–3.48 | 5.826 | 2.167–15.661 | <0.001 |
| 3.49+ | | | |
| LAAEF (%) | | | |
| 51.13+ | | | <0.001 |
| 41.79–51.12 | 1.628 | 0.613–4.321 | 0.328 |
| 30.37–41.78 | 3.081 | 1.166–8.139 | 0.023 |
| ≤30.36 | 8.255 | 2.929–23.264 | <0.001 |

Abbreviations as in Table 2.

ml/m² vs 3.67 ± 1.28 ml/m², t = 6.823, P < 0.001) in the case group were greater than those in the control group. The case group tended to have lower LAAEF (36.20 ± 10.54% vs 45.25 ± 10.07%, t = −5.875, P < 0.001) than the control group. There were no statistically significant differences between two groups in the ratio of LAAODmax to LAAODmin (1.53 ± 0.16 vs 1.56 ± 0.21, t = −1.280, P = 0.202) and the LAAD (4.61 ± 0.56 cm vs 4.45 ± 0.71 cm, t = 1.579, P = 0.116) with its correction index (2.51 ± 0.31 cm²/m² vs 2.46 ± 0.44 cm²/m², t = 0.801, P = 0.425).

The variables of LAAOA Index, LAAEF, BMI, hyperlipidemia, and the duration of atrial fibrillation were incorporated into the binary logistic regression model. Among these variables, LAAOA Index (P = 0.005) and LAAEF (P < 0.001) were statistically significant; the BMI (P = 0.205), hyperlipidemia (P = 0.222); and the duration of atrial fibrillation (P = 0.059) were not statistically significant. The resulting logistic regression model was statistically significant (χ² = 42.250, P < 0.001). After adjusting for the BMI, hyperlipidemia, and the duration of atrial fibrillation, the binary logistic regression model showed that an increase in LAAOA Index and a decrease in LAAEF were independent risk factors for cardiogenic stroke. The cardiogenic stroke risk of the highest quartile of LAAOA Index was 5.826 times (95% CI = 2.167–15.661, P < 0.001) the lowest quartile, and the risk of the lowest and the second lowest quartile of LAAEF was 8.255 times (95% CI = 2.929–23.264, P < 0.001) and 3.081 times (95% CI = 1.166–8.139, P = 0.023) the highest quartile, respectively. The model correctly classified 71.5% of the research objects. The model’s sensitivity was 70.1%, its specificity was 72.8%, its positive predictive value was 70.9%, and its negative predictive value was 72.0% (Table 3).

The receiver operating characteristic (ROC) curves of the LAAOA Index, the LAAEF and the combined predictor of LAAOA Index and LAAEF showed that the AUC value of
The difference of the AUC value between LAAOA Index and LAAEF was not statistically significant (0.022, Z = 0.448, P = 0.6544) (see Figure 3).

5. Discussion

Cardiac stroke is an important complication of atrial fibrillation (AF). The incidence of cardiogenic stroke in patients with AF is 5.6 times higher than that of sinus rhythm [9]. Compared with other types of ischemic stroke, cardiogenic stroke has more severe neurological deficits, more associated diseases, and higher recurrence, disability, and mortality [10–13]. The LAA is the main site of emboli formation in cardiogenic stroke in patients with AF. In patients with valvular atrial fibrillation (VAF), about 60% of cardiac thrombosis is formed in the LAA, and the ratio is greater than 90% in patients with nonvalvular atrial fibrillation (NVAF) [14–16]. The LAA is a remnant of the original left atrium of the embryonic period and resembles an irregular tubular diverticulum. There are significant individual differences in the morphology and size of the LAA in the physiological conditions [17, 18]. Therefore, in this study, body surface area (BSA) was used to correct each measured parameter to reduce the bias caused by this individual differences. The LAA has an active diastolic and contraction function, and it can exert certain adaptive adjustment effect when the volume load of the atrium is abnormal. When the blood flow in the LAA passes by the normal flow state and flow rate, it is difficult to form a thrombus. Pathological conditions such as atrial fibrillation can lead to changes in the structure and function of the LAA, causing eddy currents and stasis in the blood flow, which in turn leads to thrombosis [19, 20]. When the thrombus in the LAA is organized, detached, and ejected through the left ventricle, it will cause distal arterial embolization of the systemic circulation. About 80% of the embolic events occur in the cerebral blood vessels, leading to cardiogenic stroke [21]. Changes in the structure and function of the LAA affect not only the occurrence of stroke but also the progression and prognosis of stroke [22, 23].

The result of this study showed that patients with cardiogenic stroke tend to have larger LAA orifices and volumes. In agreement with this result, Khurram et al. reported that the maximum diameter of LAA orifice was positively correlated with the occurrence of cardiogenic stroke [24]. Taina et al. found that the LAA volume in patients with cardiogenic stroke was greater than that in the control group [25]. A study by Burrell et al. showed that patients with the LAA volume > 34 ml have a 7 times increased risk of ischemic stroke and embolic events compared with controls [26]. A larger LAA orifice or volume is more likely to cause a slower flow of blood in the LAA, especially at the part of orifice, and more eddy currents. Slow blood flow and eddy currents increase the chances of platelet aggregation and collision, accelerating platelet function activation, and increasing the risk of thrombosis and cardiogenic stroke. Previous studies have shown that with the progression of AF, there is an anatomic LAA remodeling, which is characterized by an increase in the volume of the LAA, an atrophy in the comb muscles, and an intimal elastic fiber tissue hyperplasia. The anatomic LAA remodeling may be one of the causes of the LAA orifice and volume to be larger in pathological conditions [27]. It is still unknown which one is the main cause of the larger LAA orifice and volume with regard to the anatomic LAA remodeling and hemodynamic changes in AF condition [27]. In view of the duration of atrial fibrillation being longer in the case group than the control group [5(3-9) yrs vs 4(2-7) yrs, Z = −2.995, P = 0.003] in this study and the causes of the difference in LAAOA and LAAV between groups, in addition to individual differences, hypertension, mitral regurgitation, and other factors, the role of atrial fibrillation progression in anatomic LAA remodeling should be considered. This study showed that the differences of the ratio of LAAODmax to LAAODmin (1.53 ± 0.16 vs 1.56 ± 0.21, t = −1.280, P = 0.202) and the LAAD (4.61 ± 0.56 cm vs 4.45 ± 0.71 cm, t =...
1.579, P = 0.116) with its correction index (2.51 ± 0.31 cm/m² vs. 2.46 ± 0.44 cm/m², t = 0.801, P = 0.425) between groups were not statistically significant, suggesting that the shape of LAA orifice and the LAA depth were not correlated with cardiogenic stroke in patients with NVAF. This conclusion needs further study to confirm.

Ono and colleagues found that the LAAEF ≤ 21% was independently associated with the LAA thrombosis [28]. Similarly, the case group has a lower LAAEF compared with the control group in this study (36.20 ± 10.54% vs 45.25 ± 10.07%, t = −5.875, P < 0.001), suggesting that the LAA emptying function in patients with cardioergic stroke tends to be weaker. The emptying obstacle of LAA leads to blood stasis and increases the risk of thrombosis and cardiogenic stroke in patients with AF. In the early stage of LAA remodeling in patients with AF, there is a myocardial atrophy and necrosis, with inflammatory cell infiltration, then endocardial elastic fiber tissue proliferation, abnormal deposition of collagen, and finally due to limited metalloproteinase activity; the LAA comb muscles are surrounded by collagen and its function is impaired, leading to the LAA emptying dysfunction, manifested by a decreased LAAEF and blood flow rate [28, 29]. The pathological changes of the LAA remodeling in patients with AF are progressively aggravated with the prolongation of the disease course of AF [27]. Due to the longer duration of atrial fibrillation in the case than control group in this study, the lower LAAEF in the case group should be related to the pathological process of the LAA remodeling. The widening of LAA orifice and the enlargement of LAA volume make it difficult for the inward movement of LAA wall to cause sufficient emptying, which causes the blood flow in LAA to become slow and stagnant and eddy currents. Severe eddy current can cause damage to the intima and can further aggravate the abnormality of platelet function, coagulation, and fibrinolysis in patients with AF [30]. These factors together constitute the pathological basis of thrombosis, which may lead to the occurrence of cardiogenic stroke.

For the secondary prevention of cardiogenic stroke in patients with atrial fibrillation, the assessment tool commonly used in clinical anticoagulant therapy is CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65-74, and sex category (female)). In this study, the demographic and clinical baseline data related to the CHA2DS2-VASc score of the two groups were overall similar to each other, and there was no statistical difference in the proportion of patients whose CHA2DS2-VASc scores ≥ 2 between the two groups (74.7% vs 71.7%, X² = 0.201, P = 0.654). However, a single assessment index often fails to meet the actual needs in clinical practice. For patients with CHA2DS2-VASc score ≤ 1 or those with ≥ 2 points with high bleeding risk, the single CHA2DS2-VASc score can lead to insufficient or excessive anticoagulation, increasing the incidence of embolism and bleeding events [31, 32]. Therefore, it is necessary to explore an assessment tool that is practical, clinically easy to use, and easy to promote for the prophylactic anticoagulant therapy for cardiogenic stroke in patients with atrial fibrillation as a supplement to the CHA2DS2-VASc score. Transesophageal echocardiography (TEE) can measure the LAA size and assess its function by hemodynamic parameters and can also visually detect the thrombus in LAA. However, as a semi-invasive examination, TEE has limited its clinical application due to its long operation time, low patient compliance, high dependence on the operation technique, potential trauma, and risk of anesthesia. The coronary CTA examination is convenient and noninvasive and has become a routine application of cardiology patients in clinical practice [33–35]. Cardiac computed tomography offers a high spatial resolution and a fast dataset acquisition, and it can provide a detailed characterization of atrial anatomy and has been shown to guide LAA closure or catheter ablation of atrial fibrillation [36]. Lopez-Minguez and colleagues evaluated the measurements obtained using computed tomography (CT), intraproper transesophageal echocardiography (IOTEE), and angiography to select the size of the closure device in LAA closure. They found that the combination of angiography-CT was the most accurate for the selection of device size [37]. This study shows that coronary CTA can provide a one-stop assessment of the anatomical shape, size, and function of LAA by data postprocessing without additional radiation dose after coronary assessment is completed. We measured the parameters of LAA size and function by coronary CTA and found that an increase in LAAOA Index (P = 0.005) and a decrease in LAAEF (P < 0.001) are independent risk factors for cardiogenic stroke, and in terms of the ROC curve analysis, the parameters of the LAAOA Index and LAAEF with the AUC value of 0.712 (95% CI = 0.639-0.777, Z = 5.570, P < 0.0001) and 0.734 (95% CI = 0.663-0.797, Z = 6.305, P < 0.0001), respectively, have medium predictive value for cardiogenic stroke in patients with NVAF. The LAAOA Index and LAAEF combined predictor with an AUC value of 0.786 (95% CI = 0.718-0.843, Z = 8.533, P < 0.0001) was superior to either LAAOA Index (Z = 2.667, P = 0.0077) or LAAEF (Z = 2.061, P = 0.0393), which indicates that a comprehensive consideration of the two factors likely leads to a more accurate judgment.

There are several potential limitations to this study. The sample size of two groups was relatively small, thus limiting the power for multivariable analyses. In addition, the predictive values of LAAOA Index and LAAEF were both medium, and neither sensitivity nor specificity of the cutoff values of LAAOA Index (3.16 cm²/m², with a sensitivity of 54.02% and a specificity of 78.26%) and LAAEF (38.71%, with a sensitivity of 62.07% and a specificity of 75.00%) was satisfactory. The reason may be that the two groups were both composed of patients with AF, and furthermore, there was no disparity of median duration years of AF between them [5 (3-9) years vs 4 (2-7) years, Z = −2.995, P = 0.003]. Therefore, the results from this study are likely more suitable for the population of AF. To obtain more valuable findings, corresponding patients without AF should be enrolled, and multicenter studies should be conducted in the future. Furthermore, this study lacks the comparison with other imaging techniques. It is expected that cases from transesophageal echocardiography, especially positive cases with LAA thrombi, will be enrolled to reinforce the study results. Finally, some unmeasured confounding may exist owing to
the limitation of the retrospective study. Although there was no statistical difference in the proportion of anticoagulants used in the two groups, there were some false negative cases caused by the anticoagulation status. Therefore, the results need to be further verified by prospective studies.

6. Conclusions

LAAOA Index and LAAEF have predictive value for cardio-
genic stroke in patients with NVAF, and the value of the two parameters combined is likely higher. In addition, the coro-
nary CTA is able to provide additional valuable imageology parameters, as a by-product of coronary artery assessment without additional radiation dose, for the risk assessment of cardiogenic stroke in NVAF, especially those with low risk of CHA2DS2-VASc score, contraindication, or intolerance to TEE. Moreover, coronary CTA may join in guiding the design of a clinical anticoagulation program to make up for the limitation of a single indicator of CHA2DS2-VASc score, so as to reduce the probability of insufficient or excessive anticoagulation and to reduce the incidence of embolism and bleeding events.

Data Availability

The testing methods and experimental data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

This work was supported by the National Key R&D Program of China (grant number 2017YFC0114300).

References

[1] C. T. January, L. S. Wann, J. S. Alpert et al., "2014 AHA/ACC/HRS guideline for the management of patients with atrial Fibrillation," Journal of the American College of Cardiology, vol. 64, no. 21, pp. e1–e76, 2014.

[2] D. Mozaffarian, E. J. Benjamin, A. S. Go et al., "Heart Disease and Stroke Statistics–2016 update: a report from the American Heart Association," Circulation, vol. 133, no. 4, pp. e8–e360, 2016.

[3] O. Lazoura, T. F. Ismail, C. Pavitt et al., "A low-dose, dual-phase cardiovascular CT protocol to assess left atrial appendage anatomy and exclude thrombus prior to left atrial intervention," The International Journal of Cardiovascular Imaging, vol. 32, no. 2, pp. 347–354, 2016.

[4] H.-F. Tse, Y.- J. Wang, M. Ahmed Ai-Abdullah et al., "Stroke prevention in atrial fibrillation—an Asian stroke perspective," Heart Rhythm, vol. 10, no. 7, pp. 1082–1088, 2013.

[5] R. G. Hart, H. C. Diener, S. B. Coutts et al., "Embolic strokes of undetermined source: the case for a new clinical construct," The Lancet Neurology, vol. 13, no. 4, pp. 429–438, 2014.

[6] R. A. G. Patel and C. J. White, "Stroke treatment and prevention," Progress in Cardiovascular Diseases, vol. 59, no. 6, pp. 525–526, 2017.

[7] V. A. Hill and A. Towfighi, "Modifiable risk factors for stroke and strategies for stroke prevention," Seminars in Neurology, vol. 37, no. 3, pp. 237–258, 2017.

[8] Y. Bai, Y. L. Wang, A. Shantsila, and G. Y. H. Lip, "The global burden of atrial fibrillation and stroke: a systematic review of the clinical epidemiology of atrial fibrillation in Asia," Chest, vol. 152, no. 4, pp. 810–820, 2017.

[9] J. S. Healey, S. J. Connolly, M. R. Gold et al., "Subclinical atrial fibrillation and the risk of stroke," The New England Journal of Medicine, vol. 366, no. 2, pp. 120–129, 2012.

[10] G. Ntaios, V. Papavasileiou, H. Milionis et al., "Embolic strokes of undetermined source in the Athens Stroke Registry: an outcome analysis," Stroke, vol. 46, no. 1, pp. 176–181, 2015.

[11] J. G. Andrade, L. Macle, S. Nattel, A. Verma, and J. Cairns, "Contemporary atrial fibrillation management: a comparison of the current AHA/ACC/HRS, CCS, and ESC Guidelines," The Canadian Journal of Cardiology, vol. 33, no. 8, pp. 965–976, 2017.

[12] P. Kirchhof, S. Benussi, D. Kotecha et al., "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS," European Heart Journal, vol. 74, no. 12, pp. 1359–1469, 2016.

[13] M. D. Ezekowitz, R. Nagarakanti, H. Noack et al., "Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart Disease," Circulation, vol. 134, no. 8, pp. 589–598, 2016.

[14] R. Pracòń, M. Demkow, A. Witkowski, and W. Rużyło, "Percutaneous elimination of the left atrial appendage in quest for effective and safe prevention of stroke in patients with atrial fibrillation," Postepy Kardiologii Interwencyjnej, vol. 10, no. 2, pp. 71–74, 2014.

[15] A. Verma, J. A. Cairns, L. B. Mitchell et al., "2014 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation," The Canadian Journal of Cardiology, vol. 30, no. 10, pp. 1114–1130, 2014.

[16] T. Sakellaridis, M. Argiriou, C. Charitos et al., "Left atrial appendage exclusion–where do we stand?" Journal of Thoracic Disease, vol. 6, suppl 1, pp. S70–S77, 2014.

[17] G. Patti, V. Pengo, R. Marcucci et al., "The left atrial appendage: from embryology to prevention of thromboembolism," European Heart Journal, vol. 38, no. 12, pp. 877–887, 2017.

[18] R. Beigel, N. C. Wunderlich, S. Y. Ho, R. Arsanjani, and R. J. Siegel, "The left atrial appendage: anatomy, function, and non-invasive evaluation," JACC: Cardiovascular Imaging, vol. 7, no. 12, pp. 1251–1265, 2014.

[19] J. F. Ren, D. J. Callans, and F. E. Marchlinski, "What is the natural relationship between left atrial appendage morphology and history of stroke," Journal of the American College of Cardiology, vol. 61, no. 6, pp. 689–690, 2013.

[20] T. Kimura, S. Takatsuki, K. Inagawa et al., "Anatomical characteristics of the left atrial appendage in cardiogenic stroke with low CHADS2 scores," Heart Rhythm, vol. 10, no. 6, pp. 921–925, 2013.

[21] M. K. Holda and M. Koziej, "Left-sided atrial septal pouch as a risk factor of cryptographic stroke: a systematic review and meta-analysis," Cerebrovascular Diseases, vol. 46, no. 5-6, pp. 223–229, 2018.
[22] Y. D. Kim, B. Park, M. J. Cha et al., "Stroke severity in concomitant cardiac sources of embolism in patients with atrial fibrillation," Journal of the Neurological Sciences, vol. 298, no. 1-2, pp. 23–27, 2010.

[23] J. Yoo, D. Song, J. H. Baek et al., "Poor outcome of stroke patients with atrial fibrillation in the presence of coexisting spontaneous Echo contrast," Stroke, vol. 47, no. 7, pp. 1920–1922, 2016.

[24] I. M. Khurram, J. Dewire, M. Mager et al., "Relationship between left atrial appendage morphology and stroke in patients with atrial fibrillation," Heart Rhythm, vol. 10, no. 12, pp. 1843–1849, 2013.

[25] M. Taina, P. Sipola, A. Muuronen et al., "Determinants of left atrial appendage volume in stroke patients without chronic atrial fibrillation," PLoS One, vol. 9, no. 3, article e90903, 2014.

[26] L. D. Burrell, B. D. Horne, J. L. Anderson, J. B. Muhlestein, and B. K. Whisenant, "Usefulness of left atrial appendage volume as a predictor of embolic stroke in patients with atrial fibrillation," American Journal of Cardiology, vol. 112, no. 8, pp. 1148–1152, 2013.

[27] H. C. Park, J. Shin, J. E. Ban, J. I. Choi, S. W. Park, and Y. H. Kim, "Left atrial appendage: morphology and function in patients with paroxysmal and persistent atrial fibrillation," The International Journal of Cardiovascular Imaging, vol. 29, no. 4, pp. 935–944, 2013.

[28] K. Ono, M. Iwama, M. Kawasaki et al., "Motion of left atrial appendage as a determinant of thrombus formation in patients with a low CHADS2 score receiving warfarin for persistent nonvalvular atrial fibrillation," Cardiovascular Ultrasound, vol. 27, no. 10, pp. 50–58, 2012.

[29] J. Shirani and J. Alaeddini, "Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography," Cardiovascular Pathology, vol. 9, no. 2, pp. 95–101, 2000.

[30] A. Shiyovich, V. Khalemeizer, and A. Katz, "New treatments for stroke and thromboembolism prevention in atrial fibrillation," Harefuah, vol. 153, no. 1, pp. 32–8, 64, 2014.

[31] S. Nedios, E. Koutalas, J. Kornej et al., "Cardiogenic stroke despite low CHA2DS2-VASc score: assessing stroke risk by left atrial appendage anatomy (ASK LAA)," Journal of Cardiovascular Electrophysiology, vol. 26, no. 9, pp. 915–921, 2015.

[32] A. Watanabe, N. Yamashita, and T. Yamashita, "Blood stasis secondary to heart failure forms warfarin-resistant left atrial thrombus," International Heart Journal, vol. 55, no. 6, pp. 506–511, 2014.

[33] J. Romero, S. A. Husain, I. Kelesidis, J. Sanz, H. M. Medina, and M. J. Garcia, "Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation," Circulation-Cardiovascular Imaging, vol. 6, no. 2, pp. 185–194, 2013.

[34] B. Xu, R. Gooley, S. K. Seneviratne, and A. Nasis, "Clinical utility of multi-detector cardiac computed tomography in structural heart interventions," Journal of Medical Imaging and Radiation Oncology, vol. 60, no. 3, pp. 299–305, 2016.

[35] R. J. Pagán, P. P. Parikh, P. J. Mergo et al., "Emerging role of cardiovascular CT and MRI in the evaluation of stroke," American Journal of Roentgenology, vol. 204, no. 2, pp. 269–280, 2015.